[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362779-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362779-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-phase-ii-trial-of-nivolumab-for-patients-with-platinum-refractory-recurrent-or-metastatic-salivary-gland-cancer-original-article","A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer - Original Article","","Salivary gland cancer is rare and clinically heterogeneous, limiting clarity on systemic treatment benefits for recurrent or metastatic disease. This phase II, multicenter study evaluated the efficacy and safety of nivolumab in patients with platinum-refractory recurrent or metastatic salivary gland cancer. Nivolumab 240 mg was given intravenously every 2 weeks, with objective response rate as the primary endpoint. Twenty-four patients were enrolled; the ORR was 8.3% and the trial did not meet the primary endpoint, with no new safety concerns observed.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-phase-ii-trial-of-nivolumab-for-patients-with-platinum-refractory-recurrent-or-metastatic-salivary-gland-cancer-original-article/362779/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-phase-ii-trial-of-nivolumab-for-patients-with-platinum-refractory-recurrent-or-metastatic-salivary-gland-cancer-original-article/362779.png","ImageObject",300,407,{"name":42,"@type":43},"Sarah ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the primary endpoint of the phase II nivolumab trial?","Question",{"text":63,"@type":64},"The primary endpoint was the objective response rate (ORR).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Who were eligible participants in this study?",{"text":68,"@type":64},"Patients with platinum-refractory recurrent or metastatic salivary gland cancer were enrolled across nine centers.",{"name":70,"@type":61,"acceptedAnswer":71},"Did nivolumab monotherapy meet the trial’s primary goal and how was safety?",{"text":72,"@type":64},"The trial did not meet its primary endpoint of ORR, and there were no new safety concerns with nivolumab monotherapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362779,1790200271,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Japanese Journal of Clinical Oncology, 2026, 56(3), 274–281 [https://doi.org/10.1093/jjco/hyaf192](https://doi.org/10.1093/jjco/hyaf192)  \nAdvance access publication date 4 December 2025  \nOriginal Article  \nA phase II trial of nivolumab for patients with  \nplatinum-refractory recurrent or metastatic salivary gland cancer  \nYoshiaki Nagatani1 ,‡, Naomi Kiyota1 ,2 ,‡* , Tomoko Yamazaki3 ,4 , Yukinori Asada5 ,  \nMasaaki Higashino6 , Hironaga Satake7 ,8 , Shogen Boku8 , Ari Nishimura9 , Hirokazu Uemura9 , Ichiro Ota10 , Katsunari Yane10 , Kaoru Tanaka11 , Takuma Onoe12 , Yuji Hirayama13 ,  \nTakahiro Tsujikawa14 , Hajime Fujiwara15 , Hikari Shimoda15 , Ken-Ichi Nibu15 , Yoshinori Imamura1 , Shiro Kimbara1 , Taiji Koyama1 , Yohei Funakoshi1 , Hironobu Minami1 ,2  \n1 Department of Medical Oncology and Hematology, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan  \n2 Kobe University Hospital Cancer Center, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan  \n3 Department of Head and Neck Oncology, Miyagi Cancer Center, 47-1 Nodayama, Medeshimashiode, Natori, Miyagi 981-1293, Japan  \n4 Department of Head and Neck Oncology Division, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka, Saitama 350-1298, Japan  \n5 Department of Head and Neck Surgery, Miyagi Cancer Center, 47-1 Nodayama, Medeshimashiode, Natori, Miyagi 981-1293, Japan  \n6 Department of Otorhinolaryngology, Head and Neck Surgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki 569-8686, Japan  \n7 Department of Medical Oncology, Kochi Medical School, Kohasu, Oko-Cho, Nankoku, Kochi 783-8505, Japan  \n8 Cancer Treatment Center, Kansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka 573-1191, Japan  \n9 Department of Otolaryngology—Head and Neck Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan  \n10 Department of Otolaryngology—Head and Neck Surgery, Kindai University Nara Hospital, 1248-1 Otoda-cho, Ikoma, Nara 630-0293, Japan  \n11 Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan  \n12 Department of Medical Oncology, Hyogo Cancer Center, 13-70, Kitaouji-cho, Akashi, Hyogo 673-8588, Japan  \n13 Department of Head and Neck Surgery, Hyogo Cancer Center, 13-70, Kitaouji-cho, Akashi, Hyogo 673-8588, Japan  \n14 Department of Otolaryngology—Head and Neck Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan  \n15 Department of Otorhinolaryngology—Head and Neck Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan  \n*Corresponding author. Department of Medical Oncology/Hematology, Cancer Center, Kobe University Hospital, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe 650-0017,  \nJapan. E-mail: [nkiyota@med.kobe-u.ac.jp](nkiyota@med.kobe-u.ac.jp)  \n‡Yoshiaki Nagatani and Naomi Kiyota contributed equally as ﬁrst authors to this work.  \nAbstract  \nBackground: Salivary gland cancer (SGC) is rare and has various histological types. This rarity and heterogeneity have hindered elucidation of the therapeutic contribution of systemic therapy, including immune checkpoint inhibitors, to recurrent or metastatic SGC (RM-SGC) . The purpose of this trial was to investigate the efﬁcacy and safety of nivolumab for platinum-refractory RM-SGC.  \nMethods: This phase II trial for platinum-refractory RM-SGC was conducted at nine centers. Nivolumab 240 mg was administered intravenously every 2 weeks. The primary endpoint was the objective response rate (ORR), and secondary endpoints were disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.  \nResults: Twenty-four patients were enrolled between March 2018 and January 2022 . The main histological types were salivary duct carcinoma (n = 10), adenoid cystic carcinoma (n = 6), and adenocarcinoma not otherwise speciﬁed (n ","cbCaigPzNMFwcj2O","https://ap.wps.com/l/cbCaigPzNMFwcj2O","pdf",829698,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the primary endpoint of the phase II nivolumab trial?\",\"answer\":\"The primary endpoint was the objective response rate (ORR).\"},{\"question\":\"Who were eligible participants in this study?\",\"answer\":\"Patients with platinum-refractory recurrent or metastatic salivary gland cancer were enrolled across nine centers.\"},{\"question\":\"Did nivolumab monotherapy meet the trial’s primary goal and how was safety?\",\"answer\":\"The trial did not meet its primary endpoint of ORR, and there were no new safety concerns with nivolumab monotherapy.\"}]","A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer - Original Article | PDF",1790149076,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/156fdaede8fe62f7f31c72530e8f2b40.webp",983,1291,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a27ca7dc41c5f5aa56171ba0fbbf069.webp",982,1290,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64629db464e011a038f6de093ea742f0.webp",981,1289,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0daa9afa11c9de85e1ce957921ff54c8.webp",980,1287]